Advances in bioinformatics and genomic data analysis have enabled the identification of cancer antigens that are generally overlooked during immune surveillance; these neoantigens have been shown to possess substantial therapeutic potential
The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
A detailed assessment of the current market landscape of developers engaged in the development of neoantigen targeted therapies.
Detailed profiles of developers of neoantigen targeted therapies (shortlisted on the basis of the number of pipeline products).
A detailed publication analysis of close to 300 peer-reviewed, scientific articles published during the period 2015-2019 (till February), highlighting the research focus within the industry.
An in-depth analysis of the various patents that have been filed / granted related to neoantigens.
An analysis of the various partnerships pertaining to neoantigen targeting therapies.
An analysis of the investments made at various stages of development in companies that are focused on developing neoantigen targeted therapies.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Target Disease Indication
Bone and Cartilage Cancer
Head and Neck Cancer
Type of Treatment
Type of Immunotherapy
Dendritic Cell Vaccine
DNA / RNA-based Vaccine
Protein / Peptide-based Vaccine
Route of Administration
Key Geographical Region
North America (US)
Europe (UK, Germany, France, Italy, and Spain
Rest of the World
Transcripts of interviews held with the following senior level representatives of stakeholder companies:
Press Release: Variation 1 (Format 2)
Gabriel Nistor, Chief Scientific Officer, AIVITA Biomedical
Ella Sorani, Vice President Research and Development, BioLineRx
Heinz Lubenau, Chief Operating Officer and Co-Founder, VAXIMM
Key companies covered in the report
For more information please click on the following link:
Other Recent Offerings
T-Cell Immunotherapies Market (4th Edition), 2019-2030
Companion Diagnostics Market (2nd Edition), 2019-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at email@example.com
Roots Analysis Private Limited
+1 (415) 800 3415